On this page
The research desk’s view
MOTS-C appears with a 15 mg product notation. No price or complete supply interval established for the 15 mg notation.
The listing, in detail
- Published service
- Boulder, Colorado clinic serving surrounding communities
- Product/menu scope
- MOTS-C appears with a 15 mg product notation.
- Cost position
- No price or complete supply interval established for the 15 mg notation
- Decision condition
- Confirm exact product, individual eligibility and complete quote before a payment commitment
What the listing establishes
- MOTS-C appears with a 15 mg product notation.
- No price or complete supply interval established for the 15 mg notation
What it leaves unanswered
- The 15 mg notation describes a product amount, not a validated individual dose or a defined number of treatment days. A comparable quote needs the prepared concentration, actual supply and clinical-service charges. None should be inferred from that number alone.
- A provider listing does not establish individual eligibility or a clinical benefit.
What a reader can establish
Rocky Mountain Regenerative Medicine enters this comparison through a specific public listing: mOTS-C appears with a 15 mg product notation. The service describes boulder, Colorado clinic serving surrounding communities. That gives a reader a real place to begin asking questions, while leaving the clinical decision individual. It does not independently verify the pharmacy, establish that the product is appropriate or promise access. The starting evidence guide is useful background because the body's own MOTS-c signal and an administered product answer different research questions.
Why this detail matters
The 15 mg notation describes a product amount, not a validated individual dose or a defined number of treatment days. A comparable quote needs the prepared concentration, actual supply and clinical-service charges. None should be inferred from that number alone.
The financial question to resolve
The public cost position is: No price or complete supply interval established for the 15 mg notation. The written-quote comparison separates a medication amount from the costs of the wider care relationship.
A research finding is not a personal forecast
The distinction becomes clearer in the linked research appraisal. Its setting was diabetic rats with liver fibrosis and complementary cell experiments, and the outcomes concerned liver injury, fibrosis and Keap1/Nrf2/Smad signaling. The study does not show that a peptide replaces exercise or treats human liver fibrosis. That observation helps a reader ask a narrower question of Rocky Mountain Regenerative Medicine: which human outcome evidence supports the exact proposal? A scientific reason for interest is not a forecast of a personal response, and a convenient care pathway does not turn the experimental system into a patient treatment trial.
The next comparison to make
For another service model, read the next provider comparison, which concerns colorado virtual peptide service with shipped-kit descriptions. The point is to compare the care arrangement and remaining questions, not imply the same product or endorse a clinical outcome. A service with a clearer price can still have unresolved clinical suitability; a consultation with no product guarantee can still provide useful assessment. We have not measured patient experience, support speed or the quality of a supplied preparation at either service.
Read the source
Research findings and provider statements are different evidence.
- Rocky Mountain Regenerative Medicine official product or clinical-service pageCompany website